Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer

Summary

The primary objective of this study is to determine in an exploratory manner the objective overall response rate to ponatinib in the treatment of patients with advanced or metastatic MTC previously treated with cabozantinib or vandetanib who have tumors with rearranged-during-transfection (RET) mutations and have tumors without RET mutations.

Timeline

Start

2019-07-26

Primary completion

2021-06-14

Completion

2021-06-14

Drugs

Indications